NCT05509699 2025-08-29Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerHutchmedPhase 2 Completed21 enrolled
NCT04579757 2025-05-08Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsHutchmedPhase 1/2 Terminated87 enrolled 29 charts